TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 478162

Group type: EXPERIMENTAL
Intervention: Domperidone (20 mg t.d.s before meals)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 14
Study: 6818587

Group type: EXPERIMENTAL
Intervention: Depot neuroleptics (fluphenazine decanoate or flupenthixol decanoate)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Fluphenazine
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Flupenthixol
Number of subjects: 41
Study: 31486723

Group type: EXPERIMENTAL
Intervention: Distribution of an advance directive (AD) with targeted ACP messaging
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: AD, messaging, plus prompting patients to engage with the Prepare For Your Care website (PREPARE)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: AD, messaging, PREPARE, plus Care Coordinator engagement with patients and clinicians
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 45
Study: 29498351

Group type: EXPERIMENTAL
Intervention: High-Ca fat-free milk phase (MD) - approximately 1500 mg of Ca/d
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low-Ca phase (CD) - approximately 800 mg of Ca/d
Number of subjects: 14
Study: 26224203

Group type: EXPERIMENTAL
Intervention: CYP3A inducers (phenobarbital, phenytoin, carbamazepine)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: CYP2C19 inducers (valproic acid, phenobarbital, phenytoin, carbamazepine)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: CYP2C19 inhibitors (felbamate, oxcarbazepine)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Concomitant use of AEDs that are either CYP450 inhibitors or inducers with clobazam
Number of subjects: 153
Study: 24625755

Group type: EXPERIMENTAL
Intervention: Chimney stove
Number of subjects: 45

Group type: COMPARATOR
Intervention: Open fire
Number of subjects: 45
Study: 22484031

Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 29

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29
Study: 20044310

Group type: EXPERIMENTAL
Intervention: Melatonin (5mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17109385

Group type: EXPERIMENTAL
Intervention: IGIV-C (Gamunex, 10%) infused at 0.08 mL/kg/min
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IGIV-C (Gamunex, 10%) infused at 0.11 mL/kg/min
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IGIV-C (Gamunex, 10%) infused at 0.14 mL/kg/min
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IGIV-C (Gamunex, 10%) at all infusion rates
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IGIV-C (Gamunex, 10%) at 0.14 mL/kg/min
Number of subjects: 36
Study: 16239186

Group type: EXPERIMENTAL
Intervention: Mechanical prostheses (Group A)
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Stented tissue prostheses (Group B)
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Stentless tissue valves (Group C)
Number of subjects: 782

Group type: COMPARATOR
Intervention: Preoperative factors (poor ejection fraction < 35%, left atrial enlargement, left bundle branch block)
Number of subjects: 782

Group type: COMPARATOR
Intervention: Perioperative variables (bypass time > 100 minutes with x-clamp time > 70 minutes)
Number of subjects: 782
Study: 11862176

Group type: EXPERIMENTAL
Intervention: Resurfacing Recovery System (RRS, Neutrogena)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Silon-TSR (Bio Med Sciences) followed by Aquaphor ointment
Number of subjects: 42
Study: 10208595

Group type: EXPERIMENTAL
Intervention: real‐rTMS applied to M1 contralaterally to the more severely affected limb
Number of subjects: 12

Group type: COMPARATOR
Intervention: sham‐rTMS applied 3 cm anteriorly to Fz
Number of subjects: 12
Study: 8548053

Group type: EXPERIMENTAL
Intervention: Octreotide (300 micrograms/day for 4 months preoperatively)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Octreotide followed by Surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 60
Study: 2237768

Group type: EXPERIMENTAL
Intervention: Sequential gradient intermittent pneumatic compression applied for 4 hours each day.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (standard treatment with ulcer debridement, cleaning, nonadherent dressing, and graduated compression stockings).
Number of subjects: 45
Study: 672548

Group type: EXPERIMENTAL
Intervention: Progressively increased pedalling rate (P)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Resistance (R)
Number of subjects: 29
Study: 31953732

Group type: EXPERIMENTAL
Intervention: Robotic pancreatoduodenectomy (RPD) using a standardized 17 steps approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized surgical approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robotic pancreatoduodenectomy (RPD)
Number of subjects: 0
Study: 31374367

Group type: EXPERIMENTAL
Intervention: Comprehensive assessments (Total Neuropathy Score, reduced)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Comprehensive assessments (Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity questionnaire)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Screening tool grading (NCI-CTCAE)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: PRO screening tools
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Addition of a brief objective test
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Screening tools
Number of subjects: 316
Study: 28957556

Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Combination therapy (infliximab or prednisone and SSZ)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 508
Study: 25692241

Group type: EXPERIMENTAL
Intervention: Double-balloon catheter
Number of subjects: 825

Group type: COMPARATOR
Intervention: Dinoprostone (3 mg)
Number of subjects: 825
Study: 23645763

Group type: EXPERIMENTAL
Intervention: NK cell-enriched lymphocytes (NKL) with docetaxel
Number of subjects: 19

Group type: COMPARATOR
Intervention: Historical control of weekly docetaxel regimen
Number of subjects: 19
Study: 20680427

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) at 24% oxygen at 1.3 ATA for 40 sessions
Number of subjects: 16
Study: 19444001

Group type: EXPERIMENTAL
Intervention: Amitriptyline (75 mg/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combined treatment (Amitriptyline 75 mg/day and Fluvoxamine 100 mg/day)
Number of subjects: 22
Study: 17185129

Group type: EXPERIMENTAL
Intervention: Gutta‐percha/AH Plus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resilon/Epiphany
Number of subjects: 0
Study: 15472643

Group type: EXPERIMENTAL
Intervention: Myocardial perfusion SPECT
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction lower than 60%
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Abnormal peak filling rate
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Abnormal time to peak filling rate
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Fixed defects
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Ejection fraction lower than 60%
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Overall mortality and complications
Number of subjects: 101
Study: 12131253

Group type: EXPERIMENTAL
Intervention: Physical activity of at least moderate intensity (30 min x d(‐1) or more)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Bicycling
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Gardening
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Decreased physical activity over the past 5 years
Number of subjects: 424
Study: 9475648

Group type: EXPERIMENTAL
Intervention: BCAA supplementation (5 mL x kg(‐1) every 30 min)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 13
Study: 8582538

Group type: EXPERIMENTAL
Intervention: Intralipid infusion (10% triglyceride emulsion) at a rate of 0.4 ml/min with heparin (200 U bolus followed by 0.2 U/min per kg body weight) for 24 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intralipid infusion (10% triglyceride emulsion) for 24 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (0.9% NaCl infusion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recovery test after discontinuation of Intralipid infusion
Number of subjects: 12
Study: 2215098

Group type: EXPERIMENTAL
Intervention: Lidocaine group (2 mL 4% lidocaine solution injected through the catheter)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no special management)
Number of subjects: 20
Study: 380941

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS), 30 mg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate (DSP), 6 mg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 90
Study: 31003229

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (300 U, mandatory ankle plantar flexors; ≤100 U, optional lower-limb muscles)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (mandatory muscles alone)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (additional injections into toe muscles: flexor digitorum longus, flexor hallucis longus)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study: 30207586

Group type: EXPERIMENTAL
Intervention: Amyloid-negative participants
Number of subjects: 269

Group type: COMPARATOR
Intervention: Amyloid-positive participants
Number of subjects: 269
Study: 26903253

Group type: EXPERIMENTAL
Intervention: Integrative Group Therapy for SMD, 11-week duration, participants stabilized on psychostimulant medication.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Community-based psychosocial treatment, control group.
Number of subjects: 68
Study: 24184523

Group type: EXPERIMENTAL
Intervention: Stent-assisted coiling
Number of subjects: 361

Group type: COMPARATOR
Intervention: Coiling alone
Number of subjects: 361
Study: 21658722

Group type: EXPERIMENTAL
Intervention: Intraperitoneal ropivacaine (Group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Peritrocal and intraperitoneal ropivacaine (Group D)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Peritrocal ropivacaine (Group C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 80
Study: 19153580

Group type: EXPERIMENTAL
Intervention: Low-fat, high-protein diet (HP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate diet (HC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Casein-supplemented HP diet
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Whey-supplemented HP diet
Number of subjects: 48
Study: 17595241

Group type: EXPERIMENTAL
Intervention: 1700 mg/d metformin treatment for 6 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) administered using a traditional incremental-dose protocol for 6 months
Number of subjects: 80
Study: 15208137

Group type: EXPERIMENTAL
Intervention: Percutaneous cholecystostomy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Gallbladder aspiration
Number of subjects: 58
Study: 11252300

Group type: EXPERIMENTAL
Intervention: levodopa/benserazide
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: tolcapone
Number of subjects: 38
Study: 9764962

Group type: EXPERIMENTAL
Intervention: 40 mg oral dose of tacrine
Number of subjects: 19
Study: 7942079

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive treatment
Number of subjects: 5
Study: 3354631

Group type: EXPERIMENTAL
Intervention: Sanding a cutting board (product-oriented activity)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sanding a piece of wood (non-product-oriented activity)
Number of subjects: 15
Study: 31593756

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy (HF) - 64.6 Gy in 19 fractions
Number of subjects: 804

Group type: COMPARATOR
Intervention: Conventionally fractionated radiation therapy (CF) - 78.0 Gy in 39 fractions
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Overall survival in HF
Number of subjects: 804
Study: 29393690

Group type: EXPERIMENTAL
Intervention: 600 µg vaginal misoprostol 6 hours before IUD insertion
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo 6 hours before IUD insertion
Number of subjects: 120
Study: 27017234

Group type: EXPERIMENTAL
Intervention: Women referred to imaging tests (adjusted odds ratio: 1.21; 95% confidence interval: 1.01 to 1.44)
Number of subjects: 10003

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 10003

Group type: COMPARATOR
Intervention: Men
Number of subjects: 10003
Study: 24622517

Group type: EXPERIMENTAL
Intervention: Continue hormone therapy (HT+)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Discontinue hormone therapy (HT-)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conjugated equine estrogen (CEE) based HT
Number of subjects: 45

Group type: COMPARATOR
Intervention: Concurrent progestins with either 17βE or CEE
Number of subjects: 45
Study: 23527013

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 400 IUs daily for 2 months
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 2000 IUs daily for 2 months
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline vitamin D deficiency (25(OH)D<20 ng/ml)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (both dosages)
Number of subjects: 8
Study: 20653150

Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 76

Group type: COMPARATOR
Intervention: BHI 30
Number of subjects: 76
Study: 17440528

Group type: EXPERIMENTAL
Intervention: Plant sterol-rich diet (2 g/day sitosterol)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plant sterol-rich diet (1 g/day sitosterol)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low cholesterol diet
Number of subjects: 30
Study: 15916620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fulfillment of the Rome criteria for study entry
Number of subjects: 45

Group type: COMPARATOR
Intervention: Increased number of office visits
Number of subjects: 45
Study: 14636092

Group type: EXPERIMENTAL
Intervention: 3 repetitions of 3-second maximal voluntary isometric contractions (MVC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (absence of prior loading)
Number of subjects: 14
Study: 10972368

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg (long-acting gastrointestinal-transport-system formulation)
Number of subjects: 6321

Group type: COMPARATOR
Intervention: Co-amilozide (hydrochlorothiazide 25 mg plus amiloride 2.5 mg)
Number of subjects: 6321

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 6321

Group type: COMPARATOR
Intervention: Co-amilozide
Number of subjects: 6321

Group type: EXPERIMENTAL
Intervention: Nifedipine and Co-amilozide
Number of subjects: 6321
Study: 8797136

Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate (1.2, 1.8, and 2.4 mg/kg i.v.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ondansetron (32 mg i.v.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8459374

Group type: EXPERIMENTAL
Intervention: Combination of droperidol, hyoscine, and metoclopramide in subtherapeutic doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Droperidol (1.25 mg) alone
Number of subjects: 0
Study: 3080868

Group type: EXPERIMENTAL
Intervention: Intralipid (50 g soya oil emulsified with egg lecithin)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lipofundin (50 g soya oil emulsified with soya lecithin)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 6
Study: 31504427

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 or 25 mg
Number of subjects: 7020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020
Study: 29468708

Group type: EXPERIMENTAL
Intervention: Pharmacist-included multidisciplinary team care (MTC) group
Number of subjects: 79

Group type: COMPARATOR
Intervention: Usual care (UC) group
Number of subjects: 79
Study: 26988798

Group type: EXPERIMENTAL
Intervention: Arjuna extract 750 mg twice daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26491093

Group type: EXPERIMENTAL
Intervention: Isolated complete right bundle branch block (n=98)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Healthy adults (control group, n=92)
Number of subjects: 98
Study: 23444397

Group type: EXPERIMENTAL
Intervention: ERN/LRPT (extended release niacin 2 g plus laropiprant 40 mg daily)
Number of subjects: 25673

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25673
Study: 21253392

Group type: COMPARATOR
Intervention: Cholecalciferol (1000 IU) and calcium citrate (800 mg) daily
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (1000 IU) and calcium citrate (800 mg) daily + sodium fluoride (25 mg bid)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (1000 IU) and calcium citrate (800 mg) daily + ibandronate (1 mg iv/3‐monthly)
Number of subjects: 148
Study: 18291177

Group type: EXPERIMENTAL
Intervention: Anticoagulation self-management (group 2, n = 470)
Number of subjects: 765

Group type: COMPARATOR
Intervention: Conventional anticoagulation management (group 1, n = 295)
Number of subjects: 765
Study: 16783144

Group type: EXPERIMENTAL
Intervention: 5% Betadine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (preservative-free artificial tears)
Number of subjects: 35
Study: 12678277

Group type: EXPERIMENTAL
Intervention: Patients with maculopathy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Late-ARMD patients
Number of subjects: 41

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 41
Study: 10886042

Group type: EXPERIMENTAL
Intervention: 1 mg alosetron
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 4 mg alosetron
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8922317

Group type: EXPERIMENTAL
Intervention: Primary directional coronary atherectomy (DCA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Primary balloon angioplasty
Number of subjects: 21
Study: 1397674

Group type: EXPERIMENTAL
Intervention: 75 mg/kg captopril
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 5 mg/day enalapril
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 30 mg/day delapril hydrochloride
Number of subjects: 28
Study: 3893601

Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Unilateral ECT
Number of subjects: 69

Group type: COMPARATOR
Intervention: Simulated ECT
Number of subjects: 69
Study: 30714866

Group type: EXPERIMENTAL
Intervention: Urinary bladder lavage (flush group; n = 69)
Number of subjects: 137

Group type: COMPARATOR
Intervention: No urinary bladder lavage (no-flush group; n = 68)
Number of subjects: 137
Study: 29635142

Group type: EXPERIMENTAL
Intervention: Treatment for panic disorder (PD)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 251
Study: 26714287

Group type: EXPERIMENTAL
Intervention: CYP3A5 genotype-based tacrolimus dosing
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard, body-weight-based tacrolimus dosing
Number of subjects: 240
Study: 25302017

Group type: EXPERIMENTAL
Intervention: 250 mg buccal acetaminophen (bAPAP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 125 mg buccal acetaminophen (bAPAP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 1 g intravenous acetaminophen (ivAPAP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 125 mg sublingual acetaminophen (sAPAP)
Number of subjects: 16
Study: 22572418

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once weekly)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral penicillin (phenoxy methyl penicillin 250 mg twice daily)
Number of subjects: 48
Study: 20840200

Group type: EXPERIMENTAL
Intervention: Brief treatment (two-session)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Extended treatment (nine-session)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Delayed treatment control condition
Number of subjects: 450
Study: 18047921

Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: valsartan 80 mg/day
Number of subjects: 40
Study: 16231111

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel (Chlorhexamed) for 15 minutes (3 x 5 min) every 12 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish (EC40) every 12 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Fluoridin) applied to all teeth 4 and 8 weeks after CHX treatments
Number of subjects: 68
Study: 11806641

Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl (smear layer intact)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 17% EDTA and 5.25% NaOCl (smear layer removed)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Vacuum method
Number of subjects: 150

Group type: COMPARATOR
Intervention: Presence or absence of smear layer
Number of subjects: 150
Study: 10527991

Group type: EXPERIMENTAL
Intervention: Single embryo transfer
Number of subjects: 110

Group type: COMPARATOR
Intervention: Double embryo transfer
Number of subjects: 110
Study: 8750365

Group type: EXPERIMENTAL
Intervention: Ramipril-chlorthalidone combination treatment (5 mg + 25 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Chlorthalidone monotherapy (25 mg daily)
Number of subjects: 32
Study: 1476027

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: KMn04 (diluted at 1:20,000)
Number of subjects: 20
Study: 6476070

Group type: EXPERIMENTAL
Intervention: Cooking activity
Number of subjects: 22

Group type: COMPARATOR
Intervention: Craft activity
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sensory awareness activity
Number of subjects: 22
Study: 31278021

Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 0